Figure 2
Figure 2. Incidence of CMV infection or disease. Kaplan-Meier curves of the cumulative incidence of CMV infection (as detected by either a positive pp65 antigenemia or positive plasma CMV DNA PCR assay, from either the central laboratory or local laboratory testing) or CMV disease in placebo and maribavir groups. P values vs placebo determined by Cox proportional hazards regression model. Symbols represent treatment groups: placebo (♦), 100 mg twice daily (●), 400 mg once daily (■), and 400 mg twice daily (▴).

Incidence of CMV infection or disease. Kaplan-Meier curves of the cumulative incidence of CMV infection (as detected by either a positive pp65 antigenemia or positive plasma CMV DNA PCR assay, from either the central laboratory or local laboratory testing) or CMV disease in placebo and maribavir groups. P values vs placebo determined by Cox proportional hazards regression model. Symbols represent treatment groups: placebo (♦), 100 mg twice daily (●), 400 mg once daily (■), and 400 mg twice daily (▴).

Close Modal

or Create an Account

Close Modal
Close Modal